Background: To evaluate patients with parotid squamous cell carcinoma (SCC) to see is it a primary or metastatic and determine the outcome of patients who metastasis to the parotid. Patients and Methods: Fifty nine patients were identified with parotid SCC through the hospital database , patients' charts, imaging studies and computerized notes. Results: Fifty patients diagnosed as metastatic SCC of parotid lymph nodes. However, 9 patients diagnosed as primary. Forty seven patients with metastatic SCC treated with surgery and post-operative radiotherapy. The median follow up of these patients was 33 months. The 3-year actuarial cause specific survival was 91%. The 3-year actuarial local recurrence free survival (LRFS) and disease free survival rate were79% and 77% respectively. Positive surgical margin after parotidectomy was the only factor that had statistically significant poor LRFS. Conclusion: The most common site of the primary tumor was a Cutaneous SCC of the face. All patients should be considered for facial sparing radical parotidectomy and adjuvant radiotherapy. Neck dissection or elective neck irradiation for ipsilateral neck is recommended due to high occult LN metastasis.
Background: Neoadjuvant chemotherapy is the standard care for locally advanced breast cancer. Our study aimed at evaluating the feasibility of breast conversation surgery (BCS) after neoadjuvant chemotherapy.
Hypofractionated conformal radiotherapy was as effective as the conventional radiotherapy, with time sparing for patients, and for radiation oncology centers. Hypofractionated radiotherapy may be considered the radiotherapy regimen of choice in clinical practice for patients with gliomas.
Purpose: Palliative treatment techniques for advanced stage rectal cancer should be designed according to the patients' major symptoms. Combined chemo-radiation therapy is effective choice for symptomatic patients with good performance status. In this study, we reviewed our patients' stage IV rectal carcinoma in regard to most common presentation, outcome and possible prognostic features. Methods Medical chart of twenty patients who were diagnosed with stage IV rectal carcinoma, were reviewed based on the hospital database information, which included images, radiotherapy charts, and their follow up notes. Results: All patients were young with age less than 40 years. Bleeding per rectum, pain, and symptoms of obstruction were the most common presentation. Seven patients had solitary lesion and 13 patients had multiple lesions. Eleven patients with multiple metastases were treated with palliative chemotherapy and radiotherapy. Patients who had solitary metastases to liver had a median survival time of 49 months versus 13.5 months for other patients (p = 0.001). Conclusion: Patients who presented with solitary liver metastases could be treated with a course of neoadjuvant chemo-radiotherapy similar to the curative one.
Introduction and Aim: Radical cystectomy is the traditional treatment of cancer bladder; however, bladder preservation in selective patients is beneficial. To evaluate the efficacy of transurethral resection plus chemo-radiation in achieving bladder preservation, using conformal radiotherapy and twice weekly Gemcitabine.
Patients and Methods:Thirty seven patients with good performance status, and maximum trans-urethral resection received 46GY /23 fractions with twice weekly Gemcitabine 30mg/m 2 . Evaluation was done after 2 weeks by cystoscopy and biopsy from the tumor bed. Patients who had complete response (CR) subjected for phase II 20 GY/10 fractions /2 weeks with twice weekly Gemcitabine 30 mg/m 2 . However, patients who had incomplete response subjected for radical cystectomy.Results: Thirty two (86.4%) patients had CR. The treatment schedule was tolerable and was associated with moderate toxicity that was easily treated. Six patients developed G3 toxicity that required treatment interruption until improvement. After 2 years of follow up, 29 patients achieved good local control with 2 years local recurrence free survival was 79%. The 2 years overall survival and bladder intact survival was 70% and 69% respectively.
Conclusions:Tri-modality bladder-sparing approach consists of transurethral resection, chemotherapy twice weekly Gemcitabine and radiotherapy is well tolerated, with high rate of bladder preservation. This approach may be considered as a reasonable alternative to cystectomy in the proper selected patients.
Introduction and aim: Laryngeal preservation with concurrent chemo-radiation is an effective, alternative management for cancer larynx. Three weekly cis-platinum concurrent with radiotherapy (RT) considered the standard. However, weekly cisplatinum has proven very effective for advanced head and neck carcinoma. We review our data to prove the efficacy and safety of weekly cis-platinum plus RT for laryngeal preservation. Patients and methods: Untreated 64 patients with advanced laryngeal carcinoma were retrospectively analyzed. Patients offered for 6 weeks of cis-platinum 40 mg/m 2 concurrent with conformal RT; 70 Gy delivered to gross primary and lymph nodes.Results: Forty-six (71.8%) patients had complete remission (CR). Early stages had better CR than late stages. Median follow up was 40 months. Three years DFS and OS were 69% and 77% respectively. Larynx preservation survival at 3 years was 73%. Protocol of treatment was tolerable, grade 3 or 4 acute and late toxic effects were reported in 25% of the included cases. Conclusion: Weekly cis-platinum could be effective and safe. We need to evaluate this protocol prospectively and compare it with three-weekly high dose cis-platinum with concomitant radiotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.